Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).

NCT01116219 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

149

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

BIOLOGICAL: bevacizumab, erlotinib
DRUG: bevacizumab, pemetrexed, cisplatin

Sponsor

Swiss Cancer Institute